This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

If you are a UK healthcare professional, visit MSD Connect for professional information.

Information for UK members of the public

This website contains information about medicines supplied by MSD in the UK. These medicines are only available on prescription and this website is not intended to replace the advice of a healthcare professional.

You can use this website to find:

  • General information about MSD medicines and vaccines
  • Information for patients who have been prescribed MSD medicines and vaccines
  • Information about diseases and treatments

You should consult your doctor or another suitably trained healthcare professional when considering what type of treatment is most appropriate for you or if you have any questions about medicines prescribed to you.

Want to know more about MSD in the UK? Please visit our corporate page:

Find out about MSD

Changes to our company portfolio

Please note that as of June 3rd 2021, MSD completed the spin-off of products from its women’s health, legacy brands, and biosimilars franchises into the new independent, publicly traded company Organon & Co.

For information on former MSD products now transferred to Organon & Co. please visit their website.

Our products are listed alphabetically in groups. You can find out more about our products by using the tabs below to display each group.

You can find out more about some of the diseases and treatment areas we provide medicines for in the list below.

Adempas® (riociguat) 0.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 1.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 1.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 2.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Adempas® (riociguat) 2.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Bridion® (sugammadex sodium) 100 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cancidas® (caspofungin acetate) 50 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cubicin® (daptomycin) 350 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Cubicin® (daptomycin) 500 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Delstrigo® (doravirine/lamivudine/tenofovir disoproxil fumarate) 100 mg/300 mg/245 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Emend® (aprepitant) 80 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Emend® (aprepitant) 125 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Emend® (aprepitant) 125 mg Powder for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Esmeron® (rocuronium bromide) 10 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics

Gardasil® (Human Papillomavirus Vaccine [Type 6,11,16,18]) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Gardasil®9 (Human Papillomavirus 9-valent vaccine) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 5 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 10 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

HBVaxPro® (hepatitis B vaccine rDNA) 40 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Invanz® (ertapenem sodium) 1 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 25 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 100 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 100 mg Granules for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 400 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Isentress® (raltegravir potassium) 600 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

IVEMEND® (fosaprepitant dimeglumine) 150 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Janumet® (sitagliptin phosphate monohydrate/metformin hydrochloride) 50 mg/1,000 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 50 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Januvia® (sitagliptin phosphate monohydrate) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Keytruda® (pembrolizumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
NICE | ClinicalTrials.gov
Further information for patients

Lenvima® (lenvatinib mesilate) 4 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lenvima® (lenvatinib mesilate) 10 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Marketing Authorisation Holder: Eisai GmbH, Lyoner Straße 36, 60528 Frankfurt am Main, Germany.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Lynparza(olaparib) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lynparza(olaparib) 150 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Lynparza(olaparib) 50 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Marketing Authorisation Holder: AstraZeneca AB, SE-151 85 Södertälje, Sweden.

MMRVaxPro® (measles, mumps and rubella vaccine [live]) Powder and Solvent for Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Moduretic® (hydrochlorothiazide/amiloride hydrochloride) 50 mg/5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics

Noxafil® (posaconazole) 300 mg Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Noxafil® (posaconazole) 100 mg Gastro-Resistant Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Noxafil® (posaconazole) 40 mg/ml Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

OncoTICE® (2-8 x 108 CFU Tice bacillus calmette-guérin) Powder for Instillation Fluid for Intravesical Use
Patient Information Leaflet | Summary of Product Characteristics

Pifeltro® (doravirine) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Pneumococcal polysaccharide vaccine (pneumococcal vaccine polyvalent) Solution for Injection in a Vial
Patient Information Leaflet | Summary of Product Characteristics

Pneumovax® 23 (pneumococcal vaccine polyvalent) Solution for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics

Prevymis® (letermovir) 240 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Prevymis® (letermovir) 240 mg Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Primaxin® IV (imipenem monohydrate/cilastatin sodium) 500 mg/500 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics

Rebetol® (ribavirin) 40 mg/ml Oral Solution
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Remicade® (infliximab) 100 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Simponi® (golimumab) 100 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients

Sivextro®(tedizolid phosphate) 200 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Sivextro®(tedizolid phosphate) 200 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Steglatro®(ertugliflozin L-pyroglutamic acid) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Steglatro®(ertugliflozin L-pyroglutamic acid) 15 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Temodal® (temozolomide) 5 mg/20 mg/100 mg/140 mg/180 mg/250 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

VAQTA® Adult (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics

VAQTA® Paediatric (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics

Varivax® (varicella virus vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics

Zepatier®(elbasvir/grazoprevir) 50 mg/100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Zerbaxa® (ceftolozane sulfate/tazobactam sodium) 1 g/0.5 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Zinplava®(bezlotoxumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.

Zostavax® (shingles [herpes zoster] vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report

Anaesthesia
Antibiotics
Ankylosing spondylitis
Aspergillosis
Cancer
Crohn's disease
Cytomegalovirus (CMV)
Diabetes
Hepatitis C
Human immunodeficiency virus (HIV)
Non-radiographic axial spondyloarthritis (nr-Axial SpA)
Psoriasis
Psoriatic arthritis
Pulmonary hypertension
Rheumatoid arthritis
Ulcerative colitis
Vaccines